Flagship named Company of the Year by CIOReview

Westminster, CO — November 13, 2018 — CIOReview has named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review.

“The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.” ~ CIOReview, November, 2018

“We make existing tissue-based assays more powerful predictive diagnostics by adding significantly more data from our cTA® platform. Our goal is to empower physicians with a scorecard that ensures the right drug gets to the right patient,” says Trevor Johnson, Flagship CEO.

CIOReview is a leading resource for innovative IT solutions. The award article highlights Flagship’s robust cTA platform and centralized, full-service solutions that streamline every step of immuno-oncology therapy development.

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts

Flagship Biosciences Is Honored with a Best Practices Award

We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...

Flagship Biosciences hires Tom Turi, Ph.D. as CSO

Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...